![Page 1: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/1.jpg)
A randomized, double‑blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 2: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/2.jpg)
Rationale for Immunotherapy in GBM
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 3: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/3.jpg)
ICT-107 is an Autologous Six-antigen DC Vaccine
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 4: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/4.jpg)
ICT-107 Phase I Highlights from ASCO 2013
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 5: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/5.jpg)
ICT-107 Ph II Trial Design
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 6: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/6.jpg)
Eligibility Criteria and Objectives
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 7: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/7.jpg)
Patient Disposition<br />October 2013 and April 2014 Data Analysis
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 8: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/8.jpg)
Patient Demographics
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 9: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/9.jpg)
Safety – Common Adverse Events
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 10: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/10.jpg)
Safety – SAEs Above Grade 3<br />Active Patients and Control Patients
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 11: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/11.jpg)
OS (From Randomization) for ITT and PP Populations<br />Updated in April 2014
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 12: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/12.jpg)
PFS for the ITT and PP Populations <br />(Central Radiology Review)<br />Updated in April 2014
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 13: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/13.jpg)
MGMT Status Creates Two Different Patient Populations From the Survival Perspective<br />Per-Protocol Population with April 2014 Survival Data
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 14: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/14.jpg)
OS in the Unmethylated MGMT and HLA-A2† Subgroup<br />Per-Protocol Population with April 2014 Survival Data
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 15: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/15.jpg)
PFS in the Unmethylated MGMT and HLA-A2 Subgroup (Central Radiology Review)<br />Per-Protocol Population with April 2014 PFS Data
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 16: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/16.jpg)
OS in the Methylated MGMT and HLA-A2 Subgroup<br />Per-Protocol Population with April 2014 Survival Data
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 17: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/17.jpg)
PFS in the Methylated MGMT and HLA-A2 Subgroup<br />(Central Radiology Review)<br />Per-Protocol Population with April 2014 PFS Data
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 18: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/18.jpg)
Quality of Life Assessed via FACT-BR and Performance Status
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 19: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/19.jpg)
Proportion of Steroid Usage During Trial
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 20: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/20.jpg)
Relationship between Indicators of Vaccine Potency and Survival<br />Cox Proportional Hazards Model – Assessments of DC Maturity and Activation in Vaccine Prior to Administration
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 21: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/21.jpg)
Antigen-Specific Vaccine Response
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 22: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/22.jpg)
Antigen Presentation in Primary Tumors<br />Percent of Patients Expressing Antigens via qPCR<br />
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 23: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/23.jpg)
Conclusions for ICT-107 Ph II
Presented By Patrick Wen at 2014 ASCO Annual Meeting
![Page 24: A randomized, double ‑ blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients](https://reader036.vdocuments.mx/reader036/viewer/2022062407/56649d085503460f949da22d/html5/thumbnails/24.jpg)
Acknowledgements
Presented By Patrick Wen at 2014 ASCO Annual Meeting